Curiosis has a line of Automated Live Cell Imaging Systems called the Celloger series. Using specialized microscopes and labeling procedures, live cell imaging enables real-time observation and ...

Monjuvi shows real-world effectiveness in relapsed/refractory DLBCL, with 11.3 months PFS and 24.8 months OS. Second-line Monjuvi treatment yields higher ORR (78.5%) compared to third-line (62.8%).

Cell migration is a multistep process fundamental to essential physiological processes, including embryonic development and immune cell migration, in addition to pathological conditions, such as tumor ...

A new commercial real estate asset class doesn’t emerge every day. However, that’s exactly what unfolded with the rise of real estate underlying cell site tower infrastructure. As pioneers in the ...

CAR T-cell therapies are individualized treatments approved for multiple hematologic malignancies, with improved management of adverse effects over time. Access to CAR T-cell therapies is limited by ...